The outbreak of the COVID 19 pandemic has led to far-reaching changes. With the Corona Update for the Campus Berlin-Buch we would like to inform you and give you a compact overview of the relevant developments and initiatives.
- Components and Services for Tests
- Services for Drug Development
- Further Innovations
- CampusLife: CampusVital
- CampusLife: Food and Drink
- CampusLife: Repair Shop
- Corona Research on the Campus
- CoronaApp of the Charité (CovApp)
- Corona Portal of the Clusters HealthCapital
Developments and Product Innovations in the BiotechPark Berlin-Buch
Developing effective tests and vaccines is an essential prerequisite for managing the corona pandemic. Innovative companies in the BiotechPark of Campus Berlin-Buch are actively contributing to this goal. They develop and produce their own tests, manufacture components for tests and offer additional services for tests or drugs.
CONGEN as an innovative test kit manufacturer, developed a test for the direct qualitative detection of the novel coronavirus (SARS-CoV-2) from human respiratory samples in a very short time. The test is a multiplex real-time RT PCR, which provides results in less than two hours. The test also contains an extraction control, which indicates a possible PCR inhibition, checks the integrity of the reagents and confirms a successful nucleic acid extraction. The test kit is very easy to use and can be performed on all common real-time PCR devices. Using all capacities, Congen started production of the molecular biological analysis kits in February. By the end of April, the company had already provided more than 1.5 million detection kits for the healthcare sector.
ImplaSens develops quantitative tests to detect the SARS-CoV-2 virus and the antibodies that patients have produced against the virus. Currently, ImplaSens will use these tests to develop a point-of-care device based on a "lab-on-a-chip" technology. This should enable users to quickly detect different antigens simultaneously without the need for laboratory equipment, even beyond COVID-19.
Glycotope will offer Covid-19 sample measurements in the near future. This will then include antibody tests in blood samples as well as tests for the detection of viral RNA using qPCR from mucosal swabs.
AJ Innuscreen develops and produces innovative technologies and products for the isolation and purification of nucleic acids and unique new rapid tests for molecular diagnostics. With these sample preparation tools, AJ Innuscreen creates the prerequisites for performing COVID-19 diagnostic tests (RT-PCR, qPCR) of other providers.
Emp Biotech is the largest independent private company in Europe for the production of solvent mixtures for diagnostic and therapeutic oligonucleotide production, of columns and chromatographic polymers for the desalting and purification of oligonucleotides. The products are used by major international diagnostics and pharmaceutical companies involved in the development of COVID-19 diagnostic tests (RT-PCR, qPCR).
EMP has four independent production facilities in Berlin, two for the manufacture of columns and chromatographic polymers and two for the production of oligonucleotide synthesis reagents.
Invitek Molecular offers a wide range of ready-to-use kits suitable for manual preparation of highly pure nucleic acids as well as for high-throughput purification of DNA/RNA from different starting materials on established laboratory equipment. With these sample preparation tools Invitek provides the prerequisites for performing COVID-19 diagnostic tests (RT-PCR, qPCR) of other suppliers.
LinusLifeScience offers services for the antibody test project with regard to Cov-2 as part of the Charite's collaboration to increase ELISA test capacity. For this test, which is currently under validation, the company provides its experience from 10 years of ELISA test development. So far, there is no reliable AK-Co-2 test; it still has to be validated. In order to be able to make reliable statements about acquired Cov-2 immunity, a joint project with the Charité will be started shortly.
The drug developer Glycotope supports Airway Therapeutics (USA) in optimizing the production process of the anti-inflammatory lung drug AT-100. Currently, the approval of Airway AT-100 as a Covid-19 therapeutic is under review. AT-100 was developed in a Glycotope cell line. In the medium term, an IgA platform for SARS virus control is to be developed.
Satina Medical has developed a respiratory stimulation belt for COPD patients that works by stimulating the diaphragm. In a clinical study it could be shown that the application of the belt increases the oxygen content in the blood back to normal values. In general, improved lung ventilation also helps to prevent pneumonia. Patients newly diagnosed with Covid-19 who are in home quarantine may benefit from the respiratory stimulation belt to prevent a severe course.
Information on the opening hours of the campus restaurants can be found here: /en/gastro.
In implementation the Ordinance on Measures to Contain the Spread of the Novel Coronavirus SARS-CoV-2 in Berlin issued by the Berlin Senate, the fitness studio at CampusVital remains closed until fitness studios in Berlin reopen. Courses will be offered as live online courses. This offer is continuously adapted and expanded to meet needs and demand.
The bicycle repair shop in Building A12 remains open.
Opening hours: Monday-Friday 11:00 am to 7:00 pm, Saturday 11:00 am to 3:00 pm.
Phone: (030) 9416 635 and 0176 44 42 40 57
The Life Science Learning Lab offers laboratory courses for school classes. The courses are held in accordance with the current distance regulations and hygiene requirements. The maximum group size will be reduced; in some cases classes will be divided between two laboratories.
The current annual program of the Gläsernes Labor Akademie can be found here: www.glaesernes-labor-akademie.de/de/programm. The course program will be online only for the first half of 2021. It is planned to offer the course again as face-to-face courses from August 2021.
In view of the pandemic, the research institutions of the Berlin-Buch Campus are pooling resources for projects that contribute to a better understanding of SARS-CoV-2. After a phase of minimal operation, the facilities have been in basic operation since April 27th.
The most up-to-date information can be obtained from the following institutions:
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP)
Berlin Institute of Health (BIH)
The CovApp is a software developed by the Charité in cooperation with Data4Life. Within a few minutes you answer a catalog of questions and receive specific recommendations for action. You will be asked questions about current symptoms and possible contacts.
The Corona portal of the HealthCapital cluster offers a compact overview of all relevant information and contact points as well as constantly updated references to new initiatives.
Weiterbildungskurs: Fachkraft für Molekularbiologie (TÜV)
VORLESUNGSREIHE "NEUE WEGE IN DER BIOMEDIZIN": SARS-Cov-2-Forschung
VORLESUNGSREIHE "NEUE WEGE IN DER BIOMEDIZIN": Neues aus der Hirnforschung